BP Heathcare | BP Lab | BP Pharmacy | BP Courier | Site Map | Contact Us
Search for
Search in WWW
Search in BP

About BP Healthcare
BP Berita
Healthcare Info
Brochures
Galleries
Handbooks
Quality Assurance
BP Network
Employment
BP Heathcare
BP Lab
BP Pharmacy
BP Courier
BP Selected Links

BP Lab is pleased to announce the availability of the following tests in our Ipoh Regional Centre with immediate effect.


1. Anti-dsDNA

Anti-dsDNA is intended for the in-vitro measurement of specific IgG autoantibodies against double stranded deoxyribonucleic acid (dsDNA) present in human serum, as an aid in the diagnosis of systemic lupus erythematosus (SLE), in conjuction with other clinical findings.

Autoantibodies to DNA recognise either single stranded (ss) or double stranded (ds)forms of DNA. Anti-ssDNA autoantibodies are not disease specific, being associated with a range of autoimmune conditions including; drug induced systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis, scleroderma and Sjogren's syndrome.

In contrast, anti-dsDNA autoantibodies are associated more specifically with SLE, where immune complex formation is thought to play a major role in the pathogenesis of the disease. The deposition of immune complexes leads to inflamation and the renal and vascular characteristics of the disease.

Sudden increases in SLE disease activity are generally preceded by a rise in anti-dsDNA levels, followed by a steep drop at the height of the disease. This observation confirms the necessity of monitoring the level of anti-dsDNA autoantibodies in SLE patients on a regular basis.

Laboratory Testing

Method ELISA
Specimen Requirement 5ml plain blood
Laboratory Interpretation Negative (<30 IU/ml)
Borderline (30-75 IU/ml)
Positive (>75 IU/ml)
Turnaround Time 1 week

Please contact our lab for further information


2. Anti-Cardiolipin Antibody

Antiphospholipid antibodies, including anti-cardiolipin antibodies, are frequently detected in sera from patients with systematic lupus erythematosus. Numerous reports have associated these autoantibodies with various venous and arterial thrombotic disorders, including cerebral infarction, deep venous thrombosis, thrombocytopenia, plumonary embolism and recurrent fetal loss with placental infarction.

In SLE and SLE-like conditions, antiphospholipids are thought to occur in between 18-61% of the patients. In the general population, the prevalence is 0-14%. So, the presence of antiphospolipids would give weight to an existing diagnosis, or certainly point toward SLE as a consideration.

Laboratory Testing

Method : ELISA
Specimen : 5ml plain blood
Turnaround Time : 1 week
Laboratory Interpretation : Positive (Absorbance >= cut off value)
  Negative (Absorbance < cut off value)

Please contact our lab for further information

 

Back to Brochures Index

 

Copyright 2002 ?BP Healthcare